Publications | Lucence

top of page

Publications

Filter by:

Clinical utility of cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) next generation sequencing (NGS) for diagnosis and treatment of leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC): a multi-centre retrospective study

Publications

Dec 1, 2025

Clinical utility of cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) next generation sequencing (NGS) for diagnosis and treatment of leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC): a multi-centre retrospective study

Clinical utility of cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) next generation sequencing (NGS) for diagnosis and treatment of leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC): a multi-centre retrospective study

High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population

Publications

Nov 13, 2025

High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population

High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population

Predictive Model for Mortality Risk
Stratification Using Laboratory
Biomarkers in Singaporeans

Publications

Nov 12, 2025

Predictive Model for Mortality Risk
Stratification Using Laboratory
Biomarkers in Singaporeans

Predictive Model for Mortality Risk Stratification Using Laboratory Biomarkers in Singaporeans

A Comprehensive Genomic Landscape of Asian and African Breast Cancer (BC) Patients

Publications

Aug 1, 2025

A Comprehensive Genomic Landscape of Asian and African Breast Cancer (BC) Patients

A Comprehensive Genomic Landscape of Asian and African Breast Cancer (BC) Patients

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

Publications

Jun 26, 2025

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay.

Publications

May 28, 2025

Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay.

Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay.

Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC).

Publications

May 28, 2025

Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC).

Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC).

Clinical actionability of an Asian pan-cancer tissue-based next generation sequencing (NGS) assay

Publications

Apr 21, 2025

Clinical actionability of an Asian pan-cancer tissue-based next generation sequencing (NGS) assay

Clinical actionability of an Asian pan-cancer tissue-based next generation sequencing (NGS) assay

Longitudinal tracking of ALK rearranged non-small cell lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA

Publications

Apr 1, 2025

Longitudinal tracking of ALK rearranged non-small cell lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA

Longitudinal tracking of ALK rearranged non-small cell lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA

1

/

8

bottom of page